Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Venous Thrombosis 3Venous Thromboembolism 3Neoplasms 3Pancreatic Neoplasms 2Venous Thormboembolism 1Thrombosis 1Thromboembolism 1Stroke 1Soft Tissue Neoplasms 1Sarcoma 1Pulmonary Embolism 1Ovarian Neoplasms 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Catheter-Related Infections 1Carcinoma, Pancreatic Ductal 1

Interventions

Gemcitabine 4Albumin-Bound Paclitaxel 3130-nm albumin-bound paclitaxel 3PEGPH20 2napabucasin 1folfirinox 1Radiotherapy 1Enoxaparin 1Dexamethasone 1Capecitabine 1Axitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Carcinoma, Pancreatic Ductal × Enoxaparin × Clear all
NCT01839487 2020-07-20

PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer

Halozyme Therapeutics

Phase 2 Completed
279 enrolled 19 charts
Gastrointestinal

Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡